文献速递心脑血管急症重症综合管理与镇静镇痛

前caplacizumab时代血栓性血小板减少性紫癜患者脑损伤模式

Pattern of Brain Injury in Patients With Thrombotic Thrombocytopenic Purpura in the Precaplacizumab Era.
PubMed 文献 · Crit Care Med · 2021-01-01
一句话结论TTP患者入院时神经系统查体可区分三种临床集群,集群1(年轻、头痛为主)神经认知完全恢复率显著高于集群2(共济失调/小脑)和集群3(谵妄/意识模糊/癫痫)。

法国单中心前瞻性队列纳入130例新诊断TTP患者,108例(83%)有神经系统体征,最常见头痛(51%)、肢体无力/感觉异常/失语(49%)、认知障碍(34%)。层次聚类分析识别出三个集群:集群1年轻、头痛为主;集群2共济失调/小脑综合征和头晕为主;集群3谵妄、意识模糊和癫痫为主,且急性肾损伤比例更高(77% vs 68% vs 32%)。中位随访34个月,93%存活,89%完全神经认知恢复(GOS 5分),集群1在3月、6月、1年时完全恢复率均显著高于集群2和3。

要点

  • 入院神经系统查体可将TTP患者分为三集群:集群1以头痛为主(75%),集群2以小脑综合征/共济失调(77%)和头晕(50%)为主,集群3以谵妄(36%)、意识模糊(58%)和癫痫(36%)为主。
  • 集群3患者急性肾损伤比例最高(77%),集群2为68%,集群1为32%(p<0.0001),提示脑损伤模式与全身器官受累相关。
  • 集群1患者3个月完全神经认知恢复(GOS 5分)比例98%,显著高于集群2(65%)和集群3(60%)(p<0.0001)。
  • 中位随访34个月,93%患者存活,89%达GOS 5分;但集群2和3的1年完全恢复率仍仅79%和57%。
  • 三集群在其它生物学指标和脑影像学上无差异,提示早期临床神经查体即可分层,无需等待影像。

适用人群与场景

  • 法国单中心ICU连续纳入的新诊断血栓性血小板减少性紫癜成人患者(年龄43 [30-52]岁,73%女性)。

诊断标准与关键阈值

  • 神经认知恢复采用Glasgow Outcome Scale评估(范围1-5分,1分代表死亡,5分代表无或极轻微神经功能缺损)。
  • 原文未提及TTP诊断标准的具体条目或阈值。

处置流程与药物剂量

  • 原文未提及具体治疗药物、剂量或处置流程。

红旗征与不能漏的情况

  • 入院时出现谵妄、意识模糊或癫痫(集群3表现)提示神经认知恢复较差,1年完全恢复率仅57%。
  • 入院时出现共济失调/小脑综合征或头晕(集群2表现)同样提示恢复较差,1年完全恢复率79%。
  • 集群3患者急性肾损伤比例高达77%,需警惕多器官受累。

研究设计与关键结果

  • 研究类型:前瞻性法国队列,单中心ICU,样本量130例新诊断TTP患者,其中108例(83%)有神经系统体征。
  • 主要发现:层次聚类分析识别三个集群,集群1年轻(37 [27-48]岁)且头痛为主(75%);集群2共济失调/小脑综合征(77%)和头晕(50%)为主;集群3谵妄(36%)、意识模糊(58%)、癫痫(36%)为主。
  • 急性肾损伤在集群1、2、3中分别为32%、68%、77%(p<0.0001);三集群其它生物学指标和脑影像学无差异。
  • 随访结果:中位随访34个月(12-71月),100例(93%)存活,89例(89%)达GOS 5分。
  • 集群1 vs 集群2 vs 集群3的GOS 5分比例:3个月为98% vs 65% vs 60%(p<0.0001);6个月为100% vs 68% vs 69%(p<0.0001);1年为100% vs 79% vs 57%(p<0.0001)。

证据类型、等级与局限

  • 证据类型:前瞻性单中心队列研究。
  • 局限:单中心、样本量130例、观察性设计,原文未提及盲法或混杂控制;聚类分析为探索性,需外部验证。

对床旁实践的改变

  • 对新诊断TTP患者,入院时详细神经系统查体(头痛、共济失调、头晕、谵妄、意识模糊、癫痫)可帮助早期识别神经恢复较差的集群(集群2和3),从而调整监护强度和家属沟通预期。
  • 集群3患者需同时关注急性肾损伤(发生率77%),加强肾功能监测。
  • 原文未提及基于集群分层的特异性治疗调整,故不能据此改变TTP治疗方案。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: To describe short- and long-term neurologic prognosis of patients with thrombotic thrombocytopenic purpura and to identify clusters associated with evolution.

DESIGN: Prospective French cohort.

SETTING: ICU in a reference center.

PATIENTS: All consecutive patients with newly diagnosed thrombocytopenic purpura.

INTERVENTION: Comprehensive clinical, biological, and radiological evaluation at admission. Neurocognitive recovery was assessed using Glasgow Outcome Scale (range 1-5, with 1 representing death and 5 representing no or minimal neurologic deficit).

MEASUREMENTS AND MAIN RESULTS: Among the 130 newly diagnosed patients with thrombocytopenic purpura, 108 (83%; age 43 [30-52]; 73% women) presented with neurologic signs, including headaches (51%), limb weakness, paresthesia, and/or aphasia (49%), pyramidal syndrome (30%), decreased consciousness (20%), seizure (19%), cognitive impairment (34%), cerebellar syndrome (18%), and visual symptoms (20%). A hierarchical cluster analysis identified three distinct groups of patients. Cluster 1 included younger patients (37 [27-48], 41 [32-52], and 48 [35-54], in clusters 1, 2 and 3, respectively; p = 0.045), with a predominance of headaches (75%, 27%, and 36%; p < 0.0001). Cluster 2 patients had ataxic gait and cerebellar syndrome (77%, 0%, and 0%; p < 0.0001) and dizziness (50%, 0%, and 0%; p < 0.0001). Cluster 3 included patients with delirium (36%, 0%, and 9%; p < 0.0001), obtundation (58%, 0%, and 24%; p < 0.0001), and seizure (36%, 0%, and 14%; p < 0.0001). Acute kidney injury was 32%, 68%, and 77%, in clusters 1, 2, and 3, respectively (p < 0.0001). The three clusters did not differ for other biological or brain imaging. After a median follow-up of 34 months (12-71 mo), 100 patients (93%) were alive with full neurocognitive recovery (i.e., Glasgow Outcome Scale score 5) in 89 patients (89%). Patients from cluster 1 more frequently exhibited full recovery (Glasgow Outcome Scale score of 5) compared with clusters 2 and 3, (44 [98%], 13 [65%], and 21 [60%] at 3 mo; p < 0.0001), (44 [100%], 15 [68%], and 23 [69%] at 6 mo; p < 0.0001), and (40 [100%], 15 [79%], and 20 [57%] at 1 yr; p < 0.0001).

CONCLUSIONS: Initial clinical neurologic evaluation in thrombocytopenic purpura patients distinguishes three groups of patients with different clinical and functional outcomes.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Mirouse A, Legriel S, Dumas G, et al. Pattern of Brain Injury in Patients With Thrombotic Thrombocytopenic Purpura in the Precaplacizumab Era. Crit Care Med. 2021. PMID: 34166282. doi:10.1097/CCM.0000000000005164

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。